Cytokines News and Research

Latest Cytokines News and Research

Gilenya offers more benefits for MS therapy than previously realized

In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.

21 Dec 2010

Clue to the blues that come with the flu

Vanderbilt University researchers may have found a clue to the blues that can come with the flu - depression may be triggered by the same mechanisms that enable the immune system to respond to infection.

21 Dec 2010

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.

21 Dec 2010

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.

20 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

Adeona expands and enhances zinc-based product candidate portfolio

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration.

16 Dec 2010

Key inhibitory role for IL-1 signaling pathway in human innate immune system

Scientists at the University of California, San Diego School of Medicine have described for the first time a key inhibitory role for the IL-1 signaling pathway in the human innate immune system, providing novel insights into human inflammatory bowel disease (IBD) and potential new treatments.

15 Dec 2010

Study: HUCBs boost survival and maturation of hippocampal neurons

Laboratory culture studies examining the activity of human umbilical cord blood cells on experimental models of central nervous system aging, injury and disease, have shown that HUCBs provide a 'trophic effect' that enhances survival and maturation of hippocampal neurons harvested from both young and old laboratory animals.

15 Dec 2010

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Immunomedics Inc. and UCB today announced the enrollment of the first patient into EMBODY™ 1, one of two pivotal Phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE). Patient enrollment for EMBODY™ 2 has also begun.

14 Dec 2010

Drug to reverse immunological decline in aging

UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age.

14 Dec 2010

Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma.

8 Dec 2010

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that consolidation treatment with fractionated yttrium-90 (Y-90) labeled epratuzumab, after induction therapy with rituximab and CHOP (R-CHOP) chemotherapy, improved remission status of adult patients with diffuse large B-cell lymphoma (DLBCL), a form of aggressive lymphoma.

7 Dec 2010

Epratuzumab-rituximab combination therapy effective against previously untreated follicular lymphoma

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that combination therapy with epratuzumab and rituximab was effective, with durable complete responses in one-third of evaluable patients, and was very well tolerated by patients with previously untreated follicular lymphoma (FL).

7 Dec 2010

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.

6 Dec 2010

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today the presentation of new preclinical data for CYC065, a novel, orally-available, cell cycle kinase inhibitor. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

6 Dec 2010

Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting

Ligand Pharmaceuticals Incorporated today announced that multiple clinical studies of dinaciclib (SCH 727965) will be presented by Merck at the upcoming 52nd American Society of Hematology Annual Meeting being held in Orlando, Florida at the Orange County Convention Center, December 4-7, 2010.

4 Dec 2010

Study on animal model may impact treatment of stroke

The results of two studies published in the current issue of Cell Transplantation (19:9) using animal models of cerebral ischemia and ischemic stroke in rats may significantly impact the treatment of stroke in humans.

2 Dec 2010

Bone marrow stromal stem cells may aid in stroke recovery: Research

A research study from the Farber Institute for Neurosciences and the Department of Neuroscience at Thomas Jefferson University determines bone marrow stromal stem cells may aid in stroke recovery. The results can be found in Cell Transplantation, The Regenerative Medicine Journal, issue 19(9).

2 Dec 2010

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of a new concept in the Current Opinion in Lipidology evaluating oxidized phospholipid analogs as potential treatments for chronic inflammatory diseases.

2 Dec 2010

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. nnounced that scientists have identified a long sought-after extracellular signaling pathway and receptor for thymosin beta 4 (Tβ4). The observation that Tβ4 increases cell surface ATP (energy produced by cells), could explain its ability to protect and regenerate tissue after ischemic injury and hypoxia (oxygen deficiency).

30 Nov 2010

Cytokines News and Research

Latest Cytokines News and Research

Gilenya offers more benefits for MS therapy than previously realized

Clue to the blues that come with the flu

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Adeona expands and enhances zinc-based product candidate portfolio

Key inhibitory role for IL-1 signaling pathway in human innate immune system

Study: HUCBs boost survival and maturation of hippocampal neurons

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Drug to reverse immunological decline in aging

Immunomedics reports CD22 antibody produced significant anti-tumor response

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Epratuzumab-rituximab combination therapy effective against previously untreated follicular lymphoma

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting

Study on animal model may impact treatment of stroke

Bone marrow stromal stem cells may aid in stroke recovery: Research

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

Scientists identify signaling pathway and receptor for thymosin beta 4

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cytokines News and Research

Latest Cytokines News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in